Protocol Ledger

NCT04607668 · Phase III · TERMINATED

Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):

Interventional Phase III clinical trial protocol NCT04607668 sponsored by G1 Therapeutics in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-01-06 Enrollment: 326 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04607668
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)326 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04607668
Protocol FieldVerified Registry Value
NCT IdentifierNCT04607668
Consolidated Lead SponsorG1 Therapeutics
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment326 participants (ACTUAL)
Registered Start Date2021-01-06
WhyStopped ClassificationUnspecified

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI